PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
35.49
+0.06 (+0.17%)
At close: 1:00PM EST
Stock chart is not supported by your current browser
Previous Close35.43
Open35.51
Bid0.00 x 0
Ask0.00 x 0
Day's Range35.37 - 35.56
52 Week Range30.51 - 36.78
Volume6,397,307
Avg. Volume16,218,475
Market Cap211.546B
Beta1.07
PE Ratio (TTM)25.96
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.28 (3.61%)
Ex-Dividend Date2017-11-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Stay away from big pharma?
    CNBC Videos4 days ago

    Stay away from big pharma?

    Carter Worth, Cornerstone Macro, discusses what stocks to avoid in the pharmaceuticals sector. The “Fast Money” traders weigh in.

  • Trump may eliminate health provision in tax bill
    Yahoo Finance Video5 days ago

    Trump may eliminate health provision in tax bill

    Republicans are willing to do just about anything to push tax reform through Congress. Even if that means dropping the repeal of the Affordable Care Act mandate, which requires that most people have health insurance or pay a penalty. Yahoo Finance’s Alexis Christoforous and Myles Udland figure the next move the GOP may take.

  • Market Realist12 hours ago

    What’s Johnson & Johnson’s Valuation?

    As of November 21, 2017, Johnson & Johnson was trading at a forward PE multiple of ~17.6x as compared to the industry average of 16.2x.

  • Value-Adding Dividend Stocks To Buy Now
    Simply Wall St.17 hours ago

    Value-Adding Dividend Stocks To Buy Now

    A great investment for income investors with a long time horizon is in dividend-paying companies like Pfizer. Dividend stocks are a safe bet to increase your portfolio value as theyRead More...

  • Market Realist2 days ago

    Teva on the Street: Analyst Recommendations in November 2017

    Teva is actively making progress toward divestiture opportunities. In November 2017, it divested Paragard to Cooper Surgical for $1.1 billion.

  • Top 10 Largest Pharmaceutical Companies By Revenue in 2017
    Insider Monkey2 days ago

    Top 10 Largest Pharmaceutical Companies By Revenue in 2017

    The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]

  • Market Realist2 days ago

    How Teva’s Generic Medicines Business Is Positioned after 3Q17

    Teva's Generic Medicine segment generated 3Q17 revenues of $3.0 billion, which was ~8% higher YoY (year-over-year) but ~2% lower QoQ (quarter-over-quarter).

  • 8 Bitcoin Stocks That You Won’t Lose Your Shirt Over
    InvestorPlace4 days ago

    8 Bitcoin Stocks That You Won’t Lose Your Shirt Over

    Bitcoin may not have the trust of Wall Street institutions just yet, but millennials are all in. Blockchain Capital recently conducted a study of 2,000 millennials (aged 18-34) and asked them to make a theoretical choice between owning $1,000 in bonds or stocks and $1,000 in bitcoin. It seems millennials are laughing all the way to the decentralized blockchain.

  • November Pharma And Biotech Dividend Stocks To Look Out For
    Simply Wall St.4 days ago

    November Pharma And Biotech Dividend Stocks To Look Out For

    Regularly affected by the ever-changing regulatory environment, the pharmaceutical and biotech industry is not one for producing the most stable cash flow. Thus, investors don’t usually associate this industry withRead More...

  • Is Merck & Co. Inc. a Buy?
    Motley Fool4 days ago

    Is Merck & Co. Inc. a Buy?

    Merck just might be poised for a rebound. But is the stock a smart long-term pick?

  • Reuters4 days ago

    Drug firm Concordia overcharged Britain's health service with 6,000 percent price rise

    Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday. The National Health Service spent 34 million pounds on liothyronine tablets last year, up from 600,000 pounds a decade ago, after Concordia increased the price per pack by almost 6,000 percent from 4.46 pounds to 258.19 pounds. CMA Chief Executive Andrea Coscelli said: "Pharmaceutical companies which abuse their position and overcharge for drugs are forcing the NHS - and the UK taxpayer - to pay over the odds for important medical treatments.

  • Reuters4 days ago

    Drug firm Concordia overcharged Britain's health service with 6,000 pct price rise

    Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday. The National Health Service spent 34 million pounds ($45 million) on liothyronine tablets last year, up from 600,000 pounds a decade ago, after Concordia increased the price per pack by almost 6,000 percent from 4.46 pounds to 258.19 pounds. CMA Chief Executive Andrea Coscelli said: "Pharmaceutical companies which abuse their position and overcharge for drugs are forcing the NHS - and the UK taxpayer - to pay over the odds for important medical treatments.

  • Reuters4 days ago

    Britain says Canada's Concordia overcharging health service for thyroid drug

    Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday. The National Health Service spent 34 million pounds ($45 million) on liothyronine tablets last year, up from 600,000 pounds a decade ago, after Concordia increased the price per pack by almost 6,000 percent from 4.46 pounds to 258.19 pounds. CMA Chief Executive Andrea Coscelli said: "Pharmaceutical companies which abuse their position and overcharge for drugs are forcing the NHS - and the UK taxpayer - to pay over the odds for important medical treatments.

  • Roche Sues Pfizer to Bar Biosimilar of Cancer Drug Herceptin
    Bloomberg4 days ago

    Roche Sues Pfizer to Bar Biosimilar of Cancer Drug Herceptin

    Roche Holding AG, facing pressure in Europe as cheaper biosimilars of its three biggest cancer medicines chew away at its revenue, sued to block Pfizer Inc. from selling a copy of its breast-cancer drug ...

  • Capital Cube4 days ago

    ETFs with exposure to Pfizer Inc. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Pfizer Inc. Here are 5 ETFs with the largest exposure to PFE-US. Comparing the performance and risk of Pfizer Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Tax reform could come before 2018, so a strategist says buy these 2 stocks
    CNBC6 days ago

    Tax reform could come before 2018, so a strategist says buy these 2 stocks

    According to one strategist, there will be two clear winners of the current GOP tax plan.

  • Associated Press7 days ago

    Nevada refusing Pfizer demand for return of execution drugs

    A Nevada prisons official said Friday the state is refusing pharmaceutical company Pfizer's demand to return a drug it manufactured and not use it in a planned lethal injection execution.

  • Nevada wants to use untried execution drugs that pose risks
    Associated Press7 days ago

    Nevada wants to use untried execution drugs that pose risks

    LAS VEGAS (AP) — For Nevada's first execution in more than a decade, state officials are turning to a never-before-tried combination of drugs, including a powerful painkiller that is fueling much of the nation's opioid epidemic and a paralyzing drug that could mask any signs of trouble.

  • Associated Press7 days ago

    The Latest: Nevada won't return execution drug to Pfizer

    The Latest on a pharmaceutical company's demand that states not use drugs it made for lethal injection executions (all times local): 5:30 p.m. An official says Nevada doesn't plan to return one of the ...

  • Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion
    Zacks7 days ago

    Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion

    Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.

  • Market Realist8 days ago

    Novartis on the Street: Analysts’ Recommendations in November

    Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold."

  • InvestorPlace8 days ago

    Why It’s Time to Put Pfizer Inc. Stock on Your Watchlist

    Ever since its cholesterol-fighting drug Lipitor lost the crux of its patent protection back in 2011, Pfizer Inc. (NYSE:PFE) investors have approached PFE stock with caution. Early this week, Purkiss made a point of saying sales of Ibrance is being underestimated, suggesting that rather than achieving just a little less than $7 billion in revenue in 2023, it could actually produce nearly $13-billion worth of business that year as its approved uses were expanded and caregivers saw its efficacy.